Transgene S.A.
TNG
Classificação em ações
#17440
Transgene SA, a French biotechnology firm headquartered in... Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Preço da ação
$0.82437785
Valor de mercado
$229.39M
Variação (1 dia)
1.02%
Variação (1 ano)
-45.19%
País
FR
Negociar Transgene S.A. (TNG)
Categoria
Healthcare
Capitalização de mercado de Transgene S.A.(TNG)
Valor de mercado: $229.39M
Em October 2026, Transgene S.A. tem uma capitalização de mercado de $229.39M. Isso faz com que Transgene S.A. seja a 17440th empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de Transgene S.A. de 2008 a 2026
TNG comparado com o topo de 5 mais populares stocks
| Preço para TNG | Ativo B | Capitalização de mercado de B | Resultados | |
|---|---|---|---|---|
$35,832.45
$117.85M
|
$5.167T | +4,384,357.19% | ||
|
$34,776.55
$117.85M
|
$5.015T | +4,255,157.28% | ||
|
$28,491.00
$117.85M
|
$4.108T | +3,486,057.20% | ||
|
$27,058.97
$117.85M
|
$3.902T | +3,310,834.31% | ||
|
$18,650.87
$117.85M
|
$2.689T | +2,282,019.91% |
